BOLD 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

BOLD ▼ -1.39% at T+20d

NEUTRAL call ✗ call lost -1.39% · α vs SPY -1.41% · entry $1.44 → $1.42

Next anchor: T+60d in 8w

Last close $1.43 (close Jun 8) · -0.69% from $1.44 entry

Entry anchored
May 8, 2026
via day open

T+1d

+7.64%

call +7.64% · α +7.41%

$1.55

settled 4w ago

T+5d

+7.64%

call +7.64% · α +6.18%

$1.55

settled 26d ago

T+20d

-1.39%

call -1.39% · α -1.41%

$1.42

settled yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Boundless Bio reported Q1 2026 results with a net loss of $13.6M, narrower than the $15.8M loss in Q1 2025, driven by lower R&D and G&A expenses. Cash burn continues, with cash reserves declining from $107.6M to $92.8M, but the company maintains runway into H2 2028. The KOMODO-1 trial for BBI-940 is enrolling, but the stock is a pre-revenue clinical-stage biotech with no revenue or earnings, making this a routine operational update with no material surprise.

Actionable Insight

This is a routine quarterly update for a pre-revenue clinical-stage biotech with no material surprises. The stock is likely to trade on KOMODO-1 trial data readouts, not quarterly financials. Monitor for initial proof-of-concept data expected within the existing cash runway timeline.

Key Facts

Net loss of $13.6M in Q1 2026 vs $15.8M in Q1 2025, a 14% improvement
Cash, cash equivalents, and short-term investments totaled $92.8M as of March 31, 2026
Cash runway expected into H2 2028, through anticipated clinical proof-of-concept readout for KOMODO-1
R&D expenses decreased to $9.7M from $12.1M year-over-year
G&A expenses decreased to $4.7M from $5.2M year-over-year
KOMODO-1 first-in-human trial of BBI-940 is open for enrollment
No revenue reported; company is a pre-revenue clinical-stage oncology biotech

Financial Impact

Net loss improved by $2.2M YoY to $13.6M; cash burn of $14.7M in Q1 2026

net_losscash_positionr&d_expensesga_expenses

Risk Factors

Clinical trial failure or delay for BBI-940
Cash burn rate may accelerate if enrollment or trial costs increase
No revenue and no approved products; fully dependent on clinical success
Potential need for future dilutive financing if cash runway shortens

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

0% bullish (7 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-213269
Document: bold-20260508.htm	0001193125-26-213269
Document: 0001193125-26-213269-index-headers.html	0001193125-26-213269
Document: 0001193125-26-213269-index.html	0001193125-26-213269
Document: 0001193125-26-213269.txt	0001193125-26-213269
8-K Data (Synthetic)	0001193125-26-213269

4 reports for BOLD

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +1.39%May 8, 2026

Filters

Reports for BOLD — sortable, filterable
	Type				Now
May 8, 2026 4w ago	8-K NEUTRAL ★ 3/10	$1.44 $1.42	▼ −1.39%	▼ −1.41%	$1.43 (−0.69%)
May 8, 2026 4w ago	Press Release BEARISH ★ 6/10	$1.44 $1.42	▲ +1.39%	▲ +1.41%	$1.43 (+0.69%)
Apr 17, 2026 7w ago	Press Release BULLISH ★ 7/10	$1.60 $1.42	▼ −11.25%	▼ −15.45%	$1.43 (−10.63%)
Apr 13, 2026 8w ago	8-K BEARISH ★ 7/10	$1.56 $1.55	▲ +0.64%	▲ +6.94%	$1.43 (+8.33%)

US Market Status

Market Closed — Opens in 6h 4m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access